Shares of micro-cap biotherapeutics company Bellerophon Therapeutics Inc BLPH gap-opened higher Friday morning and were holding on to the gains during the trading session.
The Warren, New Jersey-based company said the FDA has granted emergency expanded access for its proprietary inhaled nitric oxide delivery system, INOpulse, which would allow it to be immediately used for the treatment of COVID-19.
Nitric oxide is a naturally produced molecule that is critical to the immune response against pathogens and infections.
Lab studies have shown nitric oxide impedes replication of SARS-CoV, a strain of coronavirus that caused the SARS epidemic in 2003, according to Bellerophon. It also improved survival of cells infected by the virus.
SARS-CoV patients treated with INOpulse in clinical studies showed improvements in arterial oxygenation, a reduction in the need for ventilation support and an improvement in lung infiltrates observed on chest radiography, Bellerophon said.
Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.
Due to the genetic similarities between SARS-CoV and SARS-CoV2, the virus that causes COVID-19, INOpulse could potentially offer meaningful benefits for COVID-19 patients, according to the company.
"Importantly, INOpulse is designed to treat patients in the outpatient setting, which may be critical in helping combat the further spread of the virus and significantly alleviate the mounting impact on hospitals and intensive care units," CEO Fabian Tenenbaum said in a statement.
"We look forward to supporting patients and physicians in order to help address the current COVID-19 global health pandemic."
The stock was trading 408.85% higher at $17.25 at the time of publication Friday.
Related Links:
The $10, 10-Minute COVID-19 Test Sending Biomerica Soaring 600% In 2 Days
Photo courtesy of Bellerophon.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
